

### IN THE CLAIMS

1. (Currently Amended) An isolated polypeptide consisting of a fragment of SEQ ID NO:2, wherein the polypeptide fragment comprises ~~comprising~~ at least 15 contiguous amino acid residues of an amino acid sequence of SEQ ID NO:2 selected from the group consisting of: (a) amino acid residues ~~amino acid residues~~ 21 to 231 of SEQ ID NO:2, (b) amino acid residues 21 to 210 of SEQ ID NO:2, (c) amino acid residues 22 to 231 of SEQ ID NO:2, (d) amino acid residues 22 to 210 of SEQ ID NO:2, (e) amino acid residues 22 to 108 of SEQ ID NO:2, (f) amino acid residues 112 to 210 of SEQ ID NO:2, and (g) amino acid residues 21 to 110 of SEQ ID NO:2.

2. (Cancelled)

3. (Cancelled)

19. (Cancelled)

20. (Cancelled)

47. (Currently Amended) An isolated soluble cytokine receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 22-231 ~~or 22-210~~, wherein the soluble cytokine receptor polypeptide forms a ~~homodimeric, heterodimeric or~~ multimeric receptor complex.

48. (Currently Amended) An isolated polypeptide according to claim 47, wherein the soluble cytokine receptor polypeptide forms a ~~heterodimeric or~~ multimeric receptor complex further comprising a soluble Class I or Class II cytokine receptor.

49. (Currently Amended) An isolated polypeptide according to claim 47, wherein the soluble cytokine receptor polypeptide forms a ~~heterodimeric or~~ multimeric receptor complex comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

50. (Original) An isolated polypeptide according to claim 47, wherein the soluble cytokine receptor polypeptide further comprises an affinity tag, chemical moiety, toxin, label, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

51. (Currently Amended) An isolated ~~heterodimeric~~ or multimeric soluble receptor complex comprising soluble receptor subunits, wherein at least one of the soluble receptor subunits comprises a soluble cytokine receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 22-231 ~~or 22-240~~.

52. (Currently Amended) An isolated ~~heterodimeric~~ or multimeric soluble receptor complex according to claim 51, further comprising a soluble Class I or Class II cytokine receptor polypeptide.

53. (Currently Amended) An isolated ~~heterodimeric~~ or multimeric soluble receptor complex according to claim 51, further comprising a soluble CRF2-4 receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

67. (Cancelled)

68. (Currently Amended) An isolated soluble cytokine receptor polypeptide ~~homodimeric~~-receptor complex comprising a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid 22-231 ~~or 22-240~~.

69. (Currently Amended) The isolated soluble cytokine receptor polypeptide ~~homodimeric~~-receptor complex of claim 68, wherein the ~~homodimeric~~-receptor complex further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide,

enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

70. (Currently Amended) The isolated soluble cytokine receptor polypeptide ~~homodimeric~~ receptor complex of claim 68, wherein the ~~homodimeric~~ receptor complex binds IL-TIF (SEQ ID NO:15) or antagonizes IL-TIF activity.

71. (Newly added) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) amino acid residues 21 to 231 of SEQ ID NO:2, (b) amino acid residues 22 to 231 of SEQ ID NO:2, and (c) amino acid residues 1 to 231 of SEQ ID NO:2.

72. (Newly added) The isolated polypeptide of claim 71, wherein the polypeptide consists of an amino acid sequence selected from the group consisting of: (a) amino acid residues 21 to 231 of SEQ ID NO:2, (b) amino acid residues 22 to 231 of SEQ ID NO:2, and (c) amino acid residues 1 to 231 of SEQ ID NO:2.

73. (Newly added) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of: (a) amino acid residues 21 to 210 of SEQ ID NO:2, (b) amino acid residues 22 to 210 of SEQ ID NO:2, (c) amino acid residues 22 to 108 of SEQ ID NO:2, (d) amino acid residues 112 to 210 of SEQ ID NO:2, and (e) amino acid residues 21 to 110 of SEQ ID NO:2.

74. (Newly added) A fusion protein, comprising the polypeptide of claim 71, wherein the fusion protein binds IL-TIF (SEQ ID NO:15) or antagonizes IL-TIF activity.

75. (Newly added) The fusion protein of claim 74, wherein the fusion protein further comprises an immunoglobulin moiety.

76. (Newly added) A fusion protein, comprising the polypeptide of claim 72.
77. (Newly added) The fusion protein of claim 76, wherein the fusion protein further comprises an immunoglobulin moiety.
78. (Newly added) A fusion protein, comprising the polypeptide of claim 73.
79. (Newly added) The fusion protein of claim 78, wherein the fusion protein further comprises an immunoglobulin moiety.
80. (Newly added) The isolated polypeptide of claim 71, wherein the polypeptide further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain
81. (Newly added) The isolated polypeptide of claim 72, wherein the polypeptide further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain
82. (Newly added) The isolated polypeptide of claim 71, wherein the polypeptide binds IL-TIF (SEQ ID NO:15) or antagonizes IL-TIF activity.
83. (Newly added) The isolated polypeptide of claim 80, wherein the polypeptide binds IL-TIF (SEQ ID NO:15) or antagonizes IL-TIF activity.
84. (Newly added) The isolated soluble cytokine receptor polypeptide of claim 47, wherein the receptor complex binds IL-TIF (SEQ ID NO:15) or antagonizes IL-TIF activity.

85. (Newly added) The isolated soluble multimeric soluble receptor complex of claim 51, wherein the receptor complex binds IL-TIF (SEQ ID NO:15) or antagonizes IL-TIF activity.